 ATLANTA--BUSINESS WIRE--Virios Therapeutics, Inc. Nasdaq: VIRI, a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, today announced the closing of its initial public offering of 3,450,000 shares of its common stock at a public offering price of 10.00 per share, which includes 450,000 shares sold upon full exercise of the underwriters option to purchase additional common shares. The gross proce 